摘要
目的:从我国卫生体系的角度出发,在新版医保目录实施的背景下,评估降价后的达可替尼对比吉非替尼一线治疗EGFR突变的NSCLC的经济性。方法:基于一项三期临床试验的数据构建Markov模型,以增量成本-效果比(ICER)为指标评价达可替尼对比吉非替尼的经济性,并对结果进行敏感性分析。结果:模型运行结果显示,达可替尼相比吉非替尼的ICER为129763.86元/QALY,小于3倍的我国人均GDP,达可替尼具有成本-效果优势。敏感性分析结果显示,无进展状态的效用值和达可替尼的成本对结果的影响最大;在WTP为3倍的我国人均GDP时,达可替尼具有成本-效果优势的概率为83.04%。结论:加入医保目录降价后的达可替尼对比吉非替尼一线治疗EGFR突变的NSCLC更具有经济性。
OBJECTIVE From the perspective of China’s health system,in the context of the implementation of National Reimbursement Drug List(NRDL),to evaluate the economics of dacomitinib versus gefitinib in first-line treatment of EGFR-mutated NSCLC.METHODS A Markov model was constructed based on the data of a phase III clinical trial.The incremental cost-effectiveness ratio(ICER)was used to evaluate the economics of dacotinib versus gefitinib,and the sensitivity analysis was performed.RESULTS The model running results show that compared with gefitinib,the ICER of dacomitinib is 129763.86 CNY/QALY,which is less than 3 times China’s GDP per capita,and dacomitinib is cost-effectiveness.Sensitivity analysis results showed that the utility PFS states and the price of dacomitinib had the greatest impact on the results,when the WTP was 3 times per capita GDP of China,the probability of dacomitinib being cost-effectiveness was 83.04%.CONCLUSION Dacomitinib is a cost-effectiveness treatment over gefitinib in the first-line treatment of EGFR-mutant NSCLC after being added to the NRDL.
作者
洪望龙
夏一淼
苏广全
张旭东
方苹苹
朱文涛
郑淼淼
马国强
沈爱宗
HONG Wang-long;XIA Yi-miao;SU Guang-quan;ZHANG Xu-dong;FANG Ping-ping;ZHU Wen-tao;ZHENG Miao-miao;MA Guo-qiang;SHEN Ai-zong(School of Pharmacy,Anhui University of Chinese Medicine,Anhui Hefei 230012,China;Department of Pharmacy,Lu'an People's Hospital of Anhui Province,Anhui Lu'an 230075,China;School of Pharmacy,Anhui Medical University,Anhui Hefei 230032,China;Department of Pharmacy,The First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital),Anhui Hefei 230001,China)
出处
《中国医院药学杂志》
CAS
北大核心
2023年第8期925-930,共6页
Chinese Journal of Hospital Pharmacy
